AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
19/06/26	0.8950 €	+5.17%	243,352
18/06/26	0.8510 €	-3.30%	629,916
17/06/26	0.8800 €	+2.09%	105,830
16/06/26	0.8620 €	-2.93%	185,355
15/06/26	0.8880 €	-0.22%	116,334

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 16:55:00 19/06/2026 BST			5-day change	1st Jan Change
0.8950 ^EUR	+5.17%		+0.56%	-41.73%

06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib

Market Cap	68.5M 78.56M 63.38M 59.37M 111M 7.41B 112M 753M 292M 3.65B 295M 288M 12.67B	P/E 2025 *	-	P/E 2026 *	-
Enterprise Value	68.5M 78.56M 63.38M 59.37M 111M 7.41B 112M 753M 292M 3.65B 295M 288M 12.67B	EV / Sales 2025	95.4x	EV / Sales 2026 *	57.1x
Free-Float	67.54%	Yield 2025 *	-	Yield 2026 *	-

06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib
06-17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
06-10	AB Science presents new data on Masitinib
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
04-29	AB Science announces successful capital increase
04-28	Air Liquide, Nexans, AB Science... stocks to watch today in Paris
04-28	AB Science Reaches Maturity Extension Deal with Lenders	MT
04-27	Vinci, Lumibird, SergeFerrari... stocks to watch tomorrow in Paris
04-27	AB Science announces major agreement with creditors

06-17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
06-09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
06-02	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
05-26	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
05-25	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
06-18	Star Warsh
06-18	AB Science obtient un nouveau brevet américain pour son masitinib
06-17	Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
06-10	Bourse : Airbus veut rebondir sur le SCAF, Legrand se renforce, le marché attend Oracle

1 day	+5.17%
1 week	+0.56%
Current month	-7.16%
1 month	-7.06%
3 months	-26.28%
6 months	-29.64%
Current year	-41.73%

1 week	0.85	0.94
1 month	0.85	1
Current year	0.85	1.61
1 year	0.85	1.73
3 years	0.77	4.66
5 years	0.77	16.68
10 years	0.77	21.75

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	10/07/2001
Laurent Guy DFI	Director of Finance/CFO	-	19/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	31/03/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	10/07/2001
Patrick Moussy BRD	Director/Board Member	-	19/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	26/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-19	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
08/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
01/02/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+5.17%	+0.56%	-21.49%	-79.91%	74.76M
MERCK & CO., INC.	-1.36%	-4.35%	+43.61%	+4.16%	281B
MERCK KGAA	-0.11%	-1.85%	+21.15%	-20.06%	66.39B
HALOZYME THERAPEUTICS, INC.	-0.03%	-3.08%	+28.97%	+95.97%	8.13B
KYOWA KIRIN CO., LTD.	+1.30%	+4.49%	+1.87%	-8.18%	8.15B
SK BIOPHARMACEUTICALS CO., LTD.	-1.92%	-1.69%	-4.40%	+1.40%	4.52B
YUHAN CORPORATION	-2.69%	-0.39%	-26.62%	+36.36%	3.8B
BETTA PHARMACEUTICALS CO., LTD.	+8.33%	+4.13%	-2.52%	+13.60%	3.42B
SUPERNUS PHARMACEUTICALS, INC.	+1.84%	-2.57%	+34.65%	+31.42%	2.58B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.01%	+0.39%	+2.10%	-27.74%	1.93B
Average	+0.95%	-2.18%	+7.73%	+4.70%	38.02B
Weighted average by Cap.	-0.96%	-4.62%	+36.51%	+2.01%

	2025	2026 *
Net sales	1.1M 1.26M 1.02M 953K 1.78M 119M 1.8M 12.09M 4.68M 58.58M 4.73M 4.63M 203M	1.2M 1.38M 1.11M 1.04M 1.95M 130M 1.96M 13.19M 5.11M 63.9M 5.17M 5.05M 222M
Net income	-	-
Net Debt	-	-